ADMA Biologics, Inc.
Here’s whether ADMA Biologics, Inc. (ADMA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-9.16% over 10 days); RSI 82 — overbought, elevated pullback risk; weak 1-year return of -48.1%; 3-month momentum negative (-36.4%). Currently 57.1% off its 52-week high. Score: -7/7.
ADMA is trading below its 200-day MA ($16.20) — a key warning sign the longer-term trend is under pressure. With an RSI of 81.9, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -48.1% compares to +35.1% for SPY (trailed the market by 83.2%). The current 57.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.